{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:16Z","timestamp":1753891936398,"version":"3.41.2"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:00:00Z","timestamp":1673827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Primaquine (PQ) is an 8-aminoquinoline antimalarial, active against dormant <jats:italic>Plasmodium vivax<\/jats:italic> hypnozoites and <jats:italic>P. falciparum<\/jats:italic> mature gametocytes. PQ is currently used for <jats:italic>P. vivax<\/jats:italic> radical cure and prevention of malaria transmission. PQ is a racemic drug and since the metabolism and pharmacology of PQ\u2019s enantiomers have been shown to be divergent, the objectives of this study were to evaluate the comparative tolerability and metabolism of PQ with respect to its two enantiomers in human volunteers in a 7\u00a0days\u2019 treatment schedule. Fifteen subjects with normal glucose-6-phosphate dehydrogenase (G6PDn) completed four arms, receiving each of the treatments, once daily for 7\u00a0days, in a crossover fashion, with a 7\u201314\u00a0days washout period in between: <jats:italic>R<\/jats:italic>-(\u2212) enantiomer (RPQ) 22.5\u00a0mg; <jats:italic>S<\/jats:italic>-(+) enantiomer (SPQ) 22.5\u00a0mg; racemic PQ (RSPQ) 45\u00a0mg, and placebo. Volunteers were monitored for any adverse events (AEs) during the study period. PQ and metabolites were quantified in plasma and red blood cells (RBCs) by UHPLC-UV-MS\/MS. Plasma PQ was significantly higher in SPQ treatment group than for RPQ. Carboxy-primaquine, a major plasma metabolite, was much higher in the RPQ treated group than SPQ; primaquine carbamoyl glucuronide, another major plasma metabolite, was derived only from SPQ. The ortho-quinone metabolites were also detected and showed differences for the two enantiomers in a similar pattern to the parent drugs. Both enantiomers and racemic PQ were well tolerated in G6PDn subjects with the 7\u00a0days regimen; three subjects showed mild AEs which did not require any intervention or discontinuation of the drug. The most consistent changes in G6PDn subjects were a gradual increase in methemoglobin and bilirubin, but these were not clinically important. However, the bilirubin increase suggests mild progressive damage to a small fraction of red cells. PQ enantiomers were also individually administered to two G6PD deficient (G6PDd) subjects, one heterozygous female and one hemizygous male. These G6PDd subjects showed similar results with the two enantiomers, but the responses in the hemizygous male were more pronounced. These studies suggest that although the metabolism profiles of individual PQ enantiomers are markedly different, they did not show significant differences in the safety and tolerability in G6PDn subjects.<\/jats:p>","DOI":"10.3389\/fphar.2022.1104735","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T05:42:40Z","timestamp":1673847760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative metabolism and tolerability of racemic primaquine and its enantiomers in human volunteers during 7-day administration"],"prefix":"10.3389","volume":"13","author":[{"given":"Washim","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayan D.","family":"Chaurasiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. P. Dhammika","family":"Nanayakkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. M.","family":"Bandara Herath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gray","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald A.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric P.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"McChesney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud A.","family":"ElSohly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jollow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babu L.","family":"Tekwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1021\/jm00369a031","article-title":"Synthesis of certain hydroxy analogues of the antimalarial drug primaquine and their in vitro methemoglobin-producing and glutathione-depleting activity in human erythrocytes","volume":"27","author":"Allahyari","year":"1984","journal-title":"J. Med. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00436-019-06210-3","article-title":"Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers","volume":"118","author":"Ariffin","year":"2019","journal-title":"Parasitol. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/jms.3122","article-title":"Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling","volume":"48","author":"Avula","year":"2013","journal-title":"J. Mass Spectrom."},{"key":"B4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1471-4922(03)00005-9","article-title":"Can primaquine therapy for vivax malaria be improved?","volume":"19","author":"Baird","year":"2003","journal-title":"Trends Parasitol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"tay110","DOI":"10.1093\/jtm\/tay110","article-title":"Tafenoquine for travelers\u2019 malaria: Evidence, rationale and recommendations","volume":"25","author":"Baird","year":"2018","journal-title":"J. Travel Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1023\/A:1016363600790","article-title":"Metabolism and distribution of primaquine in Monkeys","volume":"1","author":"Baker","year":"1984","journal-title":"Pharm. Res. Off. J. Am. Assoc. Pharm. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/jps.2600770503","article-title":"Differential metabolism of the enantiomers of primaquine","volume":"77","author":"Baker","year":"1988","journal-title":"J. Pharm. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"638885","DOI":"10.3389\/fphar.2021.638885","article-title":"G6PD variants and haemolytic sensitivity to primaquine and other drugs","volume":"12","author":"Bancone","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1056\/NEJMc1301936","article-title":"Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria","volume":"369","author":"Bennett","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1124\/jpet.103.062984","article-title":"Primaquine-induced hemolytic anemia: Susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine","volume":"309","author":"Bowman","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1038\/s41467-019-11239-0","article-title":"Antimalarial activity of primaquine operates via a two-step biochemical relay","volume":"10","author":"Camarda","year":"2019","journal-title":"Nat. Commun."},{"key":"B12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4269\/ajtmh.2009.80.188","article-title":"Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment","volume":"80","author":"Carmona-Fonseca","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/ph14050398","article-title":"Enantioselective interactions of anti-infective 8-aminoquinoline therapeutics with human monoamine oxidases A and B","volume":"14","author":"Chaurasiya","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B14","first-page":"391","article-title":"Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug","volume":"59","author":"Clyde","year":"1981","journal-title":"Bull. World Health Organ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12936-016-1270-1","article-title":"Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes","volume":"15","author":"Fasinu","year":"2016","journal-title":"Malar. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12936-022-04054-4","article-title":"Comparative pharmacokinetics and tissue distribution of primaquine enantiomers in mice","volume":"21","author":"Fasinu","year":"2022","journal-title":"Malar. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12936-019-2658-5","article-title":"Formation primaquine-5, 6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes","volume":"18","author":"Fasinu","year":"2019","journal-title":"Malar. J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/1475-2875-13-507","article-title":"Enantioselective metabolism of primaquine by human CYP2D6","volume":"13","author":"Fasinu","year":"2014","journal-title":"Malar. J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1111\/jcmm.17362","article-title":"Mechanisms of 8-aminoquinoline induced haemolytic toxicity in a G6PDd humanized mouse model","volume":"26","author":"Flaherty","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.tox.2012.01.015","article-title":"Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: Evaluation of eryptotic pathway","volume":"294","author":"Ganesan","year":"2012","journal-title":"Toxicology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.taap.2009.07.012","article-title":"Cytochrome P450-dependent toxic effects of primaquine on human erythrocytes","volume":"241","author":"Ganesan","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13318-013-0139-8","article-title":"An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model","volume":"39","author":"Jin","year":"2014","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10928-005-0078-3","article-title":"Sample size computations for PK\/PD population models","volume":"32","author":"Kang","year":"2005","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B24","doi-asserted-by":"publisher","first-page":"100463","DOI":"10.1016\/j.dmpk.2022.100463","article-title":"Comparative single dose pharmacokinetics and metabolism of racemic primaquine and its enantiomers in human volunteers","volume":"45","author":"Khan","year":"","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"123517","DOI":"10.1016\/j.jchromb.2022.123517","article-title":"Quantitative analysis of primaquine and its metabolites in human urine using liquid chromatography coupled with tandem mass spectrometry","volume":"1213","author":"Khan","year":"","journal-title":"J. Chromatogr. B"},{"key":"B26","doi-asserted-by":"publisher","first-page":"122510","DOI":"10.1016\/j.jchromb.2020.122510","article-title":"Quantitative determination of primaquine-5, 6-ortho-quinone and carboxyprimaquine-5, 6-ortho-quinone in human erythrocytes by UHPLC-MS\/MS","volume":"1163","author":"Khan","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.03.011","article-title":"Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: Current state of the art","volume":"161","author":"Marcsisin","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1023\/A:1016311616719","article-title":"Synthesis of 8-(3-Carboxy-l-methyl-propylammo)-6-methoxyquinoline: A newly characterized primaquine metabolite","volume":"1","author":"McChesney","year":"1984","journal-title":"Pharm. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2125.1984.tb02369.x","article-title":"Pharmacokinetics of primaquine in man: Identification of the carboxylic acid derivative as a major plasma metabolite","volume":"17","author":"Mihaly","year":"1984","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"CD012656","DOI":"10.1002\/14651858.CD012656.pub3","article-title":"Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax","volume":"8","author":"Milligan","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1128\/AAC.00645-07","article-title":"Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3, 4- dichlorophenoxy]quinoline succinate","volume":"52","author":"Nanayakkara","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1128\/AAC.02674-13","article-title":"Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers","volume":"58","author":"Nanayakkara","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1016\/0006-2952(87)90312-1","article-title":"The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite","volume":"36","author":"Nicholl","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bcmd.2008.12.005","article-title":"The global prevalence of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis","volume":"42","author":"Nkhoma","year":"2009","journal-title":"Blood Cells. Mol. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1124\/dmd.105.006767","article-title":"Metabolism and disposition of vareniciline, a selective \u03b14\u03b22 acetyl choline receptor partial agonist, in vivo and in vitro","volume":"34","author":"Obach","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1128\/aac.00015-15","article-title":"Differential CYP 2D6 metabolism alters primaquine pharmacokinetics","volume":"59","author":"Potter","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/205507a0","article-title":"Relationship between activity of pyruvate","volume":"205","author":"Powell","year":"1965","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1475-2875-12-212","article-title":"The metabolism of primaquine to its active metabolite is dependent on CYP 2D6","volume":"12","author":"Pybus","year":"2013","journal-title":"Malar. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1475-2875-11-259","article-title":"CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine","volume":"11","author":"Pybus","year":"2012","journal-title":"Malar. J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3389\/fphys.2014.00500","article-title":"The pathophysiology of extracellular hemoglobin associated with enhanced oxidative reactions","volume":"6","author":"Rifkind","year":"2015","journal-title":"Front. Physiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1128\/aac.02576-13","article-title":"Pharmacokinetics and pharmacodynamics of (+)-Primaquine and (\u2212)-Primaquine enantiomers in Rhesus macaques (Macaca mulatta)","volume":"58","author":"Saunders","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1128\/AAC.12.1.51","article-title":"Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers","volume":"12","author":"Schmidt","year":"1977","journal-title":"Antimicrob. Agents Chemother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/infdis\/jiz386","article-title":"Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and pharmacogenomic impact on primaquine metabolism in an active-duty US Military population","volume":"220","author":"Spring","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B44","first-page":"35","article-title":"In vitro metabolism of the antimalarial agent primaquine by mouse liver enzymes and identification of a methemoglobin-forming metabolite","volume":"12","author":"Strother","year":"1984","journal-title":"Drug Metab. Dispos."},{"key":"B45","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","article-title":"Short-course primaquine for the radical cure of Plasmodium vivax malaria: A multicentre, randomised, placebo-controlled non-inferiority trial","volume":"394","author":"Taylor","year":"2019","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1124\/dmd.114.061127","article-title":"Enantioselective pharmacokinetics of Primaquine in healthy human volunteers","volume":"43","author":"Tekwani","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"B47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/QCO.0b013e328010b848","article-title":"8-Aminoquinolines: Future role as antiprotozoal drugs","volume":"19","author":"Tekwani","year":"2006","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5958\/2231-5675.2015.00035.6","article-title":"Office of clinical pharmacology in the center for drug evaluation and research and the center for veterinary medicine at the food and drug administration: Bioanalytical method validation: Guidance for industry","volume":"5","year":"2018","journal-title":"Asian J. Pharm. Analysis"},{"unstructured":"Briefing kit global messaging: World malaria report 20212021","key":"B49"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1104735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T05:42:44Z","timestamp":1673847764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1104735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,16]]},"references-count":49,"alternative-id":["10.3389\/fphar.2022.1104735"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1104735","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2023,1,16]]},"article-number":"1104735"}}